Waters Corporation (Milford, Massachusetts) and the University of Warwick, Coventry and Warwickshire, England, signed a collaborative research agreement intended to support the growth, development and adoption of novel mass spectrometry (MS) technologies.
Waters Corporation (Milford, Massachusetts) and the University of Warwick, Coventry and Warwickshire, England, signed a collaborative research agreement intended to support the growth, development and adoption of novel mass spectrometry (MS) technologies. This agreement paves the way for research projects leading to meaningful impact for analysts using biomedical mass spectrometry, validated by peer-reviewed publications, presentations at international conferences, and an outreach education program.
At the core of the collaborative agreement is the establishment of “The Waters Centre for BioMedical Mass Spectrometry” at the University of Warwick, a center of excellence in state-of-the-art MS techniques. This center will offer scientists worldwide an accessible resource to enable the adoption of cutting-edge LC–MS-based techniques in life science.“I believe that this partnership between a proven technology leader and a leading research-focused University will provide a platform for the development of many exciting new projects,” said Prof. James Scrivens, Department of Biological Sciences, University of Warwick. “I look forward to being part of a team that delivers the benefits of our research to the wider community.”
An Interview with AES Mid-Career Award Recipient Jason Dwyer
July 25th 2024Jason Dwyer of the University of Rhode Island has been named the recipient of the American Electrophoresis Society’s Mid-Career Award, which honors exceptional contributions to the field of electrophoresis, microfluidics, and related areas by an individual who is currently in the middle of their career.
Glucose's Impact on Brain Cancer Cells Unveiled Through Raman Imaging
July 25th 2024Researchers have used Raman spectroscopy and chemometric methods to reveal how glucose affects normal and cancerous brain cell metabolism. Their findings highlight specific biomarkers that can distinguish metabolic changes, potentially aiding in cancer research and treatment.